How HS Evolves Over Time — The Long-Term Disease Trajectory

The Assumption That HS Stays the Same

Most patients who have lived with HS for years describe a similar experience: the condition seemed manageable early on — an occasional painful boil, a predictable location, an antibiotic course that resolved it. Then, at some point, the pattern shifted. The intervals between episodes shortened. New sites appeared. The lesions became larger, deeper, and slower to resolve. What had once been an inconvenience became a condition that structured their daily life.

This trajectory — from occasional, manageable episodes to chronic, multi-site involvement — is not random. It follows a recognisable pattern driven by internal processes that, when left uncorrected, progressively alter the tissue environment in which HS operates. Understanding this pattern is not an academic exercise. It is the difference between treating HS as a series of isolated episodes and understanding it as a progressive process that can be interrupted — but only if intervention is directed at what is driving the progression.

Stage One — The Episodic Phase

Stage I In the earliest phase of HS, the disease typically presents as occasional, isolated nodules — painful, deep-seated, and appearing in one or two consistent locations. Episodes may occur only a few times per year. They often resolve spontaneously or with a course of antibiotics. Between episodes, the skin in the affected area appears normal.

This phase is the most commonly mischaracterised. Because the episodes resolve and the intervals between them allow a return to normal function, both patients and treating physicians tend to regard each episode as a discrete event — an infection, a blocked pore, bad luck. The fact that the same location is repeatedly involved does not trigger an investigation into why the same internal environment keeps producing the same result. The episode is treated. The environment that generated it is not.

What is happening internally during this phase is important to understand: the systemic inflammatory drivers — gut dysfunction, hormonal imbalance, metabolic disruption — are already active. They have not yet produced the structural changes that characterise later-stage disease, but they are creating a tissue environment in which follicular occlusion recurs reliably. Each episode is evidence not of bad luck but of a sustained internal state that is generating new episodes as reliably as it generated the previous one.

The Window That Closes

Stage I represents the period of greatest therapeutic opportunity. The disease is active internally, but the tissue has not yet undergone the structural changes — fibrosis, sinus tract formation, chronic discharge — that make later-stage correction significantly more complex. Internal correction at this stage can interrupt the cycle before it becomes structurally established. This is why the dismissal of early HS as "just a skin problem" has consequences that extend well beyond the immediate episode.

Stage Two — The Recurrence Pattern Establishes

Stage II As the internal drivers continue uncorrected, the interval between episodes shortens. What was once three or four episodes per year becomes monthly. New locations appear — often anatomically adjacent to the original site, or symmetrically on the other side of the body. Episodes become more severe: larger, more painful, slower to resolve.

The tissue in repeatedly affected areas begins to change. Each cycle of inflammation, rupture, and incomplete healing leaves behind subtle structural alterations — localised fibrosis, disrupted follicular architecture, early scarring. These changes make the affected tissue more vulnerable to subsequent episodes: the follicles in a previously inflamed area occlude more readily; the inflammatory response is triggered at a lower threshold; healing is slower and less complete.

Patients in this phase often describe a shift in their relationship with the condition. It is no longer something that happens occasionally. It is something they manage continuously — tracking triggers, modifying behaviour, planning around the possibility of a flare. The social and psychological weight of HS typically escalates in this phase, as the condition becomes harder to conceal and more reliably intrusive.

Stage Three — Structural Disease

Stage III In advanced HS, the disease has become structurally embedded. Sinus tracts — tunnels beneath the skin connecting multiple follicular rupture sites — develop in areas of repeated involvement. Chronic discharge becomes continuous rather than episodic. The skin overlying affected areas thickens and becomes indurated; scarring alters the architecture of the region permanently.

At this stage, surgery is often introduced as a treatment option — and in some cases it is appropriate. Sinus tracts that have become established and are causing continuous discharge may require surgical management. But surgery at this stage addresses structural consequences, not the internal process that created them. Patients who undergo wide excision for advanced HS and do not receive concurrent internal correction reliably develop new disease in adjacent areas — because the internal environment that drives HS has not changed. The territory has been cleared; the conditions that made that territory vulnerable have not.

This is not an argument against surgery. It is an argument for understanding what surgery can and cannot accomplish — and for ensuring that the internal drivers are addressed in parallel, not left to continue producing new disease in new locations.

The Systemic Dimension of Advanced HS

In Stage III disease, the impact of HS extends well beyond the skin. Chronic pain alters sleep quality, which disrupts cortisol regulation, which amplifies adrenal androgen output, which worsens the hormonal driver of HS. Chronic inflammation at this level is associated with broader metabolic dysregulation — insulin resistance worsens, inflammatory markers remain persistently elevated, and the immune system's regulatory capacity is diminished by years of sustained activation. The disease has become genuinely systemic — not just in the sense that its causes are internal, but in the sense that its effects reach every major regulatory system in the body.

What Drives the Progression — The Internal Architecture

The progression from Stage I to Stage III is not inevitable. It is driven by internal processes that, when corrected, can be interrupted at any stage — though the complexity of correction and the degree of tissue reversibility differ significantly across the stages.

Gut dysfunction sustains the systemic inflammatory baseline that makes follicular occlusion reliably recurrent. As long as the gut is generating a persistent inflammatory signal, the tissue environment remains primed for HS activity regardless of what is done at the skin level.

Hormonal imbalance — particularly androgen excess and insulin resistance — creates the follicular susceptibility through which the inflammatory signal expresses itself. Without correction of the hormonal environment, the specific follicular vulnerability that HS exploits remains intact.

Immune dysregulation determines the severity of the inflammatory response to follicular disruption. In HS, this response is characteristically amplified — producing more tissue damage, more extensive scarring, and a more established structural disease than would occur in an immune system operating within normal regulatory parameters.

These three drivers interact with each other and compound over time. Gut dysfunction worsens hormonal regulation; hormonal imbalance amplifies immune dysregulation; immune dysregulation causes tissue damage that worsens the local environment for subsequent episodes. Each year of uncorrected internal disease is not simply another year at the same level of severity — it is a year in which the internal architecture of the disease becomes more established and the tissue consequences accumulate.

Why Stage Matters — The Practical Implication

Understanding the disease trajectory is not simply intellectually useful. It has direct practical implications for what treatment can achieve.

At Stage I, the internal drivers are active but the tissue is structurally intact. Correction of the internal environment can prevent the structural changes that make later-stage disease more complex to manage. The goal at this stage is interruption: stop the cycle before it becomes embedded.

At Stage II, internal correction remains highly effective — but tissue restoration becomes an additional component of treatment. It is not sufficient to reduce the inflammatory load; the tissue that has already been affected needs active support in restructuring. Treatment takes longer and requires more comprehensive systemic engagement.

At Stage III, internal correction is still both possible and necessary — but structural consequences may require parallel management. The tissue changes of advanced HS are not fully reversible in all cases; the goal becomes preventing further progression and new-site involvement while improving quality of life as substantially as the existing structural picture allows.

What This Means for How HS Is Approached

The dominant clinical model for HS management — sequential antibiotic courses, topical preparations, hormonal suppressants, and surgery for advanced cases — is organised around responding to episodes rather than interrupting the trajectory. Each intervention addresses the current manifestation of the disease without altering the internal architecture generating it. This is why the trajectory continues: because what drives it has not been addressed.

An approach organised around trajectory interruption looks different. It begins with understanding which internal drivers are active — gut, hormonal, immune, or some combination — and addresses them as the primary therapeutic target. Surface manifestations are managed supportively, but they are not the primary target of treatment. The goal is to alter the internal environment in which HS operates, such that the trajectory of progression is interrupted and, where possible, reversed.

This requires personalised evaluation — not because personalisation is a marketing concept, but because the specific combination of internal drivers differs between patients. A 28-year-old woman with PCOS-driven hormonal HS has a different internal architecture than a 45-year-old man with metabolic syndrome-driven HS, even if their skin presentations are superficially similar. The trajectory is the same; the engine driving it is different; the correction required is therefore different.